680 results about "Atrophy" patented technology

A physical and mental health status monitor, analyze and follow up clothing system. Whose purpose is to monitor the user's body fat distribution, muscular activity and position changes to diagnose health status. Regularly giving suggestions to the user to achieve proper exercise and posture to reduce body fat and prevent muscular atrophy. While correcting the user's life style to promote better health, this system also works to reduce mental and emotional stress. Providing better healthcare and reducing the chance of disease. This system includes sensors, a close range monitoring system and long range monitoring stations, through the sensors it collects data for the monitoring system and monitoring stations to observe, analyze, diagnose and follow up on the user's physical and mental state. This system also allows the user and the long range monitoring stations to communicate with each other through the close range monitoring system.

A saddle-shaped compression device and methods of fastening a dysfunctional intervertebral disc are used to (1) compress a protrusion to alleviate nerve impingement, (2) fortify the annulus to stabilize a motion segment, (3) minimize the inward/outward bulging and delamination of the annulus, (4) atrophy the nerve to treat discogenic pain, (5) correct the curvature of spinal deformities, (6) elevate the disc space to treat spinal stenosis, and (7) seal the seepage of nucleus pulposus from a herniated disc.

Presently, many variations of light treatment are used in health care. Prime examples are the in-vivo or ex-vivo photodynamic treatment (PDT) of skin diseases, cancer/tumors, psoriasis, mood disorders, bladder infections, promoting wound closure, recovering spinal cord injuries, and countering muscle/bone atrophy. PDT is a treatment that uses a drug, called a photo-sensitizer or photosensitizing agent, and a particular type of light. The invention relates to an improved PDT device.

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIIIth nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIIIth nerve atrophy, and the hearing loss and possible deafness that accompany them.

The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with compounds of Formula (I) are disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods are also disclosed.

Methods for measuring atrophy in a brain region occupied by the hippocampus and entorhinal cortex. In one example, MRI scans and a computational formula are used to measure the medial-temporal lobe region of the brain over a time interval. This region contains the hippocampus and the entorhinal cortex, structures allied with learning and memory. Each year this region of the brain shrank in people who developed memory problems up to six years after their first MRI scan. The method is also applicable for measuring the progression rate of atrophy in the region in an instance where the onset of Alzheimer's disease has already been established.

The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.

Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with vitamin K are disclosed.

Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.

An adjustable brace includes a first portion for supporting one surface of a patient and a plurality of adjustable portions that allow the internal cross section of the brace to be adjusted. When a limb is injured, a patient may have a swollen limb and the adjustable brace can be set to a large cross section. As the limb heals, the swelling decreases and the limb cross section also decreases due to atrophy. The adjustable couplings are adjusted to reduce the cross section to properly fit the limb of the patient and provide proper protection and support during the healing process.

The invention provides a myoelectric signal-controlled master-slave wireless functional electric stimulation rehabilitation system in the technical field of rehabilitation medical treatment. The system comprises a master unit and a slave unit, wherein the master unit is connected with a master side to transmit myoelectric information; the master unit is in wireless connection with the slave unit to transmit motion mode information; and the slave unit is connected with a slave side to transmit electrical pulse information. The master unit comprises a plurality of EMG electrode plates, an amplifier, a filter, an encoder and a wireless transmitter; and the slave unit comprises a wireless receiver, a controller, an electrical stimulator and a plurality of FES electrode plates. By using the system, a physical therapist assists a paralyzed patient to do training without physical contact, and a plurality of patients can do rehabilitation trainings following the same physical therapist, so the workload of the physical therapist is greatly lightened; meanwhile, the system can keep the muscle vitality of the patient, prevent muscular atrophy, reduce convulsion and help the patient achieve more ideal rehabilitation effect.

This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.

The invention relates to a stable preparation of phosphatidylserine and a preparation method, application as well as an application product of the stable preparation. The preparation method comprises the following step of processing the phosphatidylserine through microencapsulation, micro-pelletization or liposome encapsulation. The stable preparation of the phosphatidylserine can be independently applied as a medicine or can be added into daily foods, drinks and health-care products, also has an important effect on health care of brains while guaranteeing the color and the taste of the daily foods and the drinks of people and is of great benefit to brain disorder such as nutritional supplement of brain development of students, overstrain of nerves of the adults, and memory loss, brain atrophy and senile dementia of the middle aged and elderly people.

The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathic, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).

A rehabilitation training device with anti-convulsant and anti-thrombotic functions for stroke patients comprises a bed frame, a supporting plate and a control mechanism, wherein the supporting plate consists of a fixed part and a rotating part which are hinged to each other; a head and neck support is arranged at one end of the supporting plate; an electrode plate capable of releasing stimulation pulses is arranged on the outer surface of the head and neck support; and the rotating part can be pushed upwards or return downwards. A push-and-pull rod II is arranged at the tail end of the fixed part, and front-back swinging training of a front section of a sole of a patient can be realized. A forearm fixing plate and a shank fixing plate are arranged on the supporting plate, electrode plates are distributed on the surface of the forearm fixing plate and the surface of the shank fixing plate, and the forearm fixing plate and the shank fixing plate can drive the upper limbs or lower limbs of the patient to finish left-right swinging and front-back flexion and extension movements. By the rehabilitation training device, sitting-up and lying-down training, continuous transformation of functional positions of upper affected limbs and lower affected limbs, anti-convulsant training of front-back swinging of soles of both feet and pulse massaging stimulation of the stroke patient can be implemented automatically, muscle spasm and atrophy of the bedridden stroke patient are avoided effectively, and rapid recovery of the stroke patient is promoted.

The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathic, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

The present invention features a method of treating atrophy of skin or mucosal tissue by administering to skin or mucosal tissue in need of such treatment a composition including a tensioning polymer, said method selected from the group consisting of thickening said skin or mucosal tissue, enhancing extracellular matrix production in said skin or mucosal tissue, and enhancing the barrier function of said skin or mucosal tissue.